The Future of Pharmaceutical Manufacturing Now
Aprecia is the leader in advanced additive manufacturing for the pharmaceutical industry that enables oral drug delivery through novel formulations and dosage forms.
Over 20 Years of Innovation
Founded in 2003, Aprecia Pharmaceuticals is a pioneering force in additive manufacturing, dedicated to revolutionizing drug delivery through three-dimensional printing (3DP) technology. With over 20 years of innovation, Aprecia remains the first and only 3DP company in the world to achieve regulatory product approval, bringing groundbreaking products like Spiritam® to market. Boasting 126 granted patents and 52 pending, Aprecia’s commitment to innovation is unmatched. Aprecia is led by a team of seasoned pharmaceutical experts and continues to develop unique pharmaceutical products through global partnerships, leveraging technology originally developed at MIT. Our commitment to quality and regulatory compliance is reflected in our exemplary track record—our facility has undergone three FDA inspections, including the most recent in 2019, with no 483s issued.
The first and only 3D-printed pharmaceutical product. Spritam validated Aprecia’s unique ability to utilize 3DP as a formulation and manufacturing platform for a high dose orodispersible. Spritam is licensed to Prasco Laboratories and is now being produced in Aprecia’s cGMP manufacturing facility.
Our Culture
Our Vision
Aprecia is focused on becoming the global leader in new pharmaceutical technologies that address unmet healthcare needs.
Our Mission
Aprecia’s goal is to maximize our 3DP technology through unique pharmaceutical products and global partnerships.
Our Purpose
Aprecia is building a successful healthcare technology company through innovation and faith.
A Depth of Expertise
Aprecia brings together a team with deep knowledge and a proven track record of solving the industry’s toughest challenges.
Our Leadership TeamOur Collaborations
Aprecia is committed to partnering with innovative researchers, manufacturers, and technology companies across the pharmaceutical life cycle in ways that allow us to enhance the value of our technologies and advance the possibilities of pharmaceutical product development.
Development engineering support for equipment design and prototyping
Business development and commercialization support in Japan
Access to multiparticulate technologies and services
Access to functional excipients
Access to nanoparticle technologies and services
Fostering educational leadership, talent development, and R&D support to drive innovation
Collaborating to nurture talent, take a leadership role in education, and support groundbreaking research and development
Provides critical medications for pediatric and adult patients across the country